Mercy Research

1. Pfizer Inc. $891,064 406 payments
2. CVRx, Inc. $573,443 59 payments
3. Novartis Pharmaceuticals Corporation $546,602 3 payments
4. Amgen Inc. $448,619 55 payments
5. AbbVie, Inc. $351,059 123 payments
6. Medtronic Vascular, Inc. $333,223 31 payments
7. Genentech, Inc. $330,261 77 payments
8. Medtronic, Inc. $258,467 74 payments
9. Merck Sharp & Dohme Corporation $231,969 19 payments
10. Baxter Healthcare $212,479 21 payments

1. Study name not reported $560,443 54 payments
2. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $546,602 3 payments
3. TAVR Low Risk $357,168 35 payments
4. A Lowinterventional Study to Assess Gdf15 Levels in Adult Participants With Cachexia and Malignant Solid Tumors $308,974 90 payments
5. Starling Registry $212,479 21 payments
6. A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation MK-7684A Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer KEYVIBE-003 $171,522 2 payments
7. Ocrelizumab in Patients With RMS $123,078 8 payments
8. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $119,147 24 payments
9. TAVR Low Risk CAS $115,669 10 payments
10. A Randomized Openlabel Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab Msb0010718c in Combination With Andor Following Chemotherapy in Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 $112,908 12 payments

1. Other $279,926 24 payments
2. Patient care $51,600 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.